trial

Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

NCTId NCT00320671
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 198 (actual)
Sponsored by Northwell Health, Early Treatment Program at Lenox Hill
Primary completion 2014-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
198 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2005-12
Primary completion
2014-12
Eligibility
ALL · 15 Years · 40 Years

Interventions & indications

Drugs
AripiprazoleRisperidone

Sponsors

Northwell Health, Early Treatment Program at Lenox HillLead Sponsor
National Institute of Mental Health (NIMH)Collaborator

Investigators

1
Delbert G. Robinson, MDPrincipal Investigator

Sites

1 total
Glen Oaks, United States

Facts & assertions

4 sourced
Enrollment
198
Phase
PHASE4
Primary Completion Date
2014-12
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
Risperidone
drug
lead_sponsor
Northwell Health, Early Treatment Program at Lenox Hill
company
collaborator
National Institute of Mental Health (NIMH)
company
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
investigator
Delbert G. Robinson, MD
person